ProCE Banner Activity

Long-Term Safety of Baricitinib in Patients with Rheumatoid Arthritis: Updated Findings from All-BARI-RA Analysis Set

Slideset Download
Conference Coverage
Baricitinib demonstrates acceptable safety in RA patients exposed for up to 7 yrs

Released: June 28, 2019

Expiration: June 26, 2020

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Gilead

Lilly

Sanofi Genzyme and Regeneron Pharmaceuticals